Related Experiment Video
Updated: Jun 26, 2026
09:15
In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Bivalirudin: a new promising direct antithrombin
Anupam Bhambhani1, Bernhard Meier
1Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.
Indian Heart Journal
|January 7, 2009
Summary
Bivalirudin is a direct antithrombin agent that effectively inhibits thrombin and platelet aggregation in ischemic heart disease. It offers a promising alternative to heparin, with reduced bleeding risks and no risk of heparin-induced thrombocytopenia.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Intra-coronary thrombin generation drives ischemic heart disease.
- Thrombin bound to fibrin or collagen resists heparin inactivation.
- Direct antithrombins target thrombin's active sites, bypassing heparin limitations.
Purpose of the Study:
- To review the clinical impact of bivalirudin, a direct antithrombin agent.
- To highlight bivalirudin's mechanism of action and efficacy in cardiology.
Main Methods:
- Focus on bivalirudin, a short-acting anticoagulant.
- Bivalirudin directly and bivalently inhibits thrombin at catalytic and fibrinogen-binding sites.
- Inhibition of protease-activated receptors 1 and 4 (PAR1 and PAR4) by bivalirudin.
Main Results:
- Bivalirudin demonstrates clinical efficacy in acute coronary syndromes, percutaneous coronary interventions, and cardiac surgery.
- It effectively inhibits thrombin-mediated platelet aggregation.
- Compared to unfractionated heparin, bivalirudin shows a trend towards lower bleeding risks without compromising efficacy.
Conclusions:
- Bivalirudin is a potent direct antithrombin with high affinity and specificity for thrombin.
- Its unique mechanism offers advantages over heparin, including no risk of heparin-induced thrombocytopenia.
- Bivalirudin presents a promising therapeutic option in interventional and non-interventional cardiology.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...